2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
1990
Serotonin-Specific Drugs for Anxiety and Depressive Disorders
Charney DS, Krystal JH, Delgado PL, Heninger GR. Serotonin-Specific Drugs for Anxiety and Depressive Disorders. Annual Review Of Medicine 1990, 41: 437-446. PMID: 2139556, DOI: 10.1146/annurev.me.41.020190.002253.Peer-Reviewed Original Research
1989
Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects
Woods S, Krystal J, Heninger G, Charney D. Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sciences 1989, 45: 233-242. PMID: 2503670, DOI: 10.1016/0024-3205(89)90255-5.Peer-Reviewed Original ResearchConceptsHealthy human subjectsClonidine 2 mcg/Pulse rateEffects of alprazolamAnxiety-like effectsHuman subjectsRatings of anxietyOral alprazolamHypotensive effectVentilatory responseMcg/Noradrenergic systemBenzodiazepine receptorsAnxiolytic propertiesNeurobiologic mechanismsClonidineNew drugsAlprazolamAnxiety ratingsSubjective anxietyDrugsAnxietyNormal functioningNeural systemsUseful model system